Biography
Professor Anthony Chan, MD, FRCP (Lond, Edin, Glas), graduated from the School of Medicine in University College London and received post-graduate training in Medical Oncology at the Royal Marsden Hospital, UK, and joined The Chinese University of Hong Kong (CUHK) in 1993 where he was formerly Dean of Graduate School, and is currently Pro-Vice-Chancellor of CUHK, Li Shu Fan Medical Foundation Professor of Clinical Oncology, Director of the Sir YK Pao Centre for Cancer, Director of the Hong Kong Cancer Institute, Chief Director of Phase 1 Clinical Trial Centre, Associate Director of the State Key Laboratory of Translational Oncology (CUHK) and Master of Wu Yee Sun College.
Professor Chan conducted pivotal studies setting new treatment standards in multimodality approaches in nasopharynx cancer, developed the clinical applications of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease. He has published extensively in international journals, and also delivered hundreds of international lectures. He has published reviews in Lancet and Nature Reviews Clinical Oncology as well as European Society for Medical Oncology (ESMO) treatment guidelines for Nasopharyngeal Cancer. He has served on the Editorial Board of Journal of Clinical Oncology and has been Associate Editor of Annals of Oncology since 2014. Professor Chan was honoured with the 2023 ESMO Lifetime Achievement Award in recognition for his leadership and outstanding research in nasopharyngeal cancer.
Professor Chan has extensive experience in committee and advisory board services for professional, government and non-government organizations. He is Honorary Consultant of Department of Health, Cluster Coordinator (Clinical Oncology) of Hong Kong Hospital Authority (New Territories East Cluster), Vice-President of Hong Kong College of Physicians, and a member of the Medical Advisory Committee (MAC) of CUHK Medical Centre Limited.
